SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.

The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.
Metastatic Colorectal Cancer
DRUG: SHR-1210|DRUG: BP102|DRUG: oxaliplatin|DRUG: capecitabine
Safety of the combination therapy: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment, From sign icf to the end of follow-up, 24 months|Objective response rate, From sign icf to occurrence of objective response (complete regression (CR) and partial regression (PR) need to be confirmed 28 days after the occurrence), 24 months
DOR, Duration of response ,DOR, 24 months|DCR, Disease Control Rate，DCR, 24 months|PFS, Progression free survival,PFS, 24 months|9month PFS rate, Month 9 PFS rate,PFS9m, 9 months|12month and 24 month OS rate, Overall survival rate: the time from the date of icf to the date of documented clinical or radiological progression or death due to any cause within 12 and 24 months after first visit, 24 months
Biomarkers and ADA, PD-L1、MSI、TMB expression and ADA, 24 months
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.

The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.